Pharmeasy to seek funding from Manipal only in case of shortfall in rights issue
The Manipal Group's family office had made a binding offer to invest up to Rs 1,300 crore in the online pharmacy
Stay updated with breaking news from Api Holdings. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Manipal Group's family office had made a binding offer to invest up to Rs 1,300 crore in the online pharmacy
Earlier, it was reported that Manipal Group has offered to invest approximately Rs 1,300 crore for an 18 per cent stake in API Holdings.
PharmEasy is faced with a steep cut in its valuation, with the new funding round pegging its shares at Rs 5 each compared to the Rs 50 per share that it secured in 2021. The huge fall in value has triggered questions about the fate of Velumanis purchase of a 5% stake in the firm in 2021 when it was valued at $4 billion.
The board notified its shareholders about increasing the authorised share capital to Rs 3,500 crore (about $423.72 million), divided into 3,000 crore equity shares of Re 1 each, and 500 crore preference shares of Re 1 each. A company increases its authorised share capital to pump in new money from investors.
The firm had plans to raise ₹6,250 crore via its IPO but had deferred the issue, citing market conditions and strategic considerations. At that time, the company had said that it would instead raise funds from existing shareholders via a rights issue